Shi-Yi Wang, MD, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is an Associate Professor at the Yale School of Public Health, faculty member of Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, and faculty member of Public Health Modeling Concentration, Yale School of Public Health. His primary interests focus on outcomes research and decision science. He is interested in combining systematic literature reviews, secondary data analyses, and simulation modeling to examine issues that are critical to clinicians and policy makers’ decision making. He has been working on several breast cancer projects, including an evaluation of preoperative breast MRI, development of an individualized decision aid to help radiotherapy decision-making, and assessment of sentinel lymph node biopsy for patients with ductal carcinoma in situ. He is also evaluating end-of-life care quality. He has served as the primary investigator or co-investigator in several projects (funded by Yale Cancer Center, AHRQ, NCI, ACS, and PCORI).
Last Updated on April 07, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimaryChronic Disease Epidemiology
LecturerSecondary
Other Departments & Organizations
Education & Training
- PhD
- University of Minnesota (2012)
- MD
- Taipei Medical College (1992)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Terminal Care
Public Health Interests
Aging; End-of-life Care; Health Care Quality, Efficiency; Global Health; Cancer; Modeling
ORCID
0000-0002-3294-5784
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shi-Yi Wang's published research.
Publications Timeline
A big-picture view of Shi-Yi Wang's research output by year.
Research Interests
Research topics Shi-Yi Wang is interested in exploring.
Cary P Gross, MD
Michael S. Leapman, MD, MHS
Sarah Westvold, MPH
Natalia Kunst, PhD
Xiaomei Ma, PhD
Michaela Dinan, PhD
110Publications
3,569Citations
Breast Neoplasms
Terminal Care
Publications
2025
Personalized risk assessment of frailty in long-term cancer survivors
Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsFrailty indexPersonalized risk assessmentDelivery of survivorship careStage I-III breastCancer diagnosisLong-term cancer survivorsCancer survivor populationAssessment of frailtyClinical prediction ruleSurvivorship careFive-year survivorsCancer survivorsSurvivor populationFrailty progressionPost-diagnosisMedicare dataRisk stratification toolHigh-risk groupRestricted mean survival timeFrailtyEnd ResultsSignificant predictorsLong-term survivorsSurvivorsStratification toolSmoldering multiple myeloma in the United States: A population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: A population-based analysis. Blood Advances 2025 PMID: 41213002, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricRisk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer
Taylor M, Westvold S, Long J, Hyslop T, Silber A, Forman R, Yasin F, Kwaramba T, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Network Open 2025, 8: e2544812. PMID: 41296485, PMCID: PMC12658655, DOI: 10.1001/jamanetworkopen.2025.44812.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSurvivors of breastLate-onset depressionCancer survivorsAssociated with greater hazardCohort studyLong-term survivors of breastDual eligiblesColorectal cancerMedicare-Medicaid dual eligibilityCancer diagnosisLong-term cancer survivorsColorectal cancer survivorsFee-for-service MedicareBreast cancer survivorsComorbidity burdenProstate cancer survivorsPrevalence of depressionRisk of depressionFollow-up careMedicaid dual eligibilityFee-for-serviceDiagnosis of anxietyRisk factorsLow-risk tertileAssociated with greater riskMolecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 23: 461-467. PMID: 41072474, DOI: 10.6004/jnccn.2025.7063.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerLong test turnaround timesNon-small cell lung cancerCell lung cancerRetrospective cohort studyTest turnaround timeNext-generation sequencingTargeted therapyClinical outcomesAssociated with worse median progression-free survivalLung cancerUS patientsElectronic health record-derivedMedian progression-free survivalRetrospective cohort study of patientsNontarget treatmentCohort study of patientsProgression-free survivalTargetable genomic alterationsFirst-line treatmentHistory of smokingStudy of patientsNGS useEGFR testingNontargeted therapiesCardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer
Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, djaf243. PMID: 41069232, DOI: 10.1093/jnci/djaf243.Peer-Reviewed Original ResearchThis study investigates cardiovascular risk in older long-term cancer survivors, showing non-cancer factors, rather than cancer-specific ones, predict late-onset cardiovascular disease.Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
Kunst N, Long J, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Network Open 2025, 8: e2539250. PMID: 41134573, PMCID: PMC12552925, DOI: 10.1001/jamanetworkopen.2025.39250.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsPSMA-PETBiochemical recurrenceProstate cancerProstate-specific membrane antigen positron emission tomographyLow prostate-specific antigen levelsBiochemically recurrent prostate cancerProstate-specific antigen levelMetastatic prostate cancerProstate cancer evaluationStudy of patientsUS academic centersLifetime quality-adjusted life yearsTreatment costsCost-effectiveness ratioPositron emission tomographyDecision-analytic modelDefinitive surgeryRadiation therapyMolecular imagingAntigen levelsBone scanPatient subsetsReflex testAssociation Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis. Clinical Lymphoma Myeloma & Leukemia 2025, 25: e942-e949. PMID: 40670211, DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchConceptsSmoldering Multiple MyelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesBiomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchAltmetricRisk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
Kwaramba T, Westvold S, Long J, Hyslop T, Silber A, Lustberg M, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Dinan M. Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors. Journal Of Clinical Oncology 2025, 43: 1642-1642. DOI: 10.1200/jco.2025.43.16_suppl.1642.Peer-Reviewed Original ResearchConceptsSurvivors of breastRectal cancer survivorsCancer survivorsYears post-diagnosisPost-diagnosisOlder survivorsScreen-detectedSEER-MedicareLong-term cancer survivorsNon-screened cancersLong-term breastStage I-III cancerProstate cancer survivorsIndex cancer diagnosisContinuous Medicare Parts ASEER-Medicare dataModifiable risk factorsMedicare Part ADiagnosis of SPMSurvivorship careSEER-Medicare databaseSurvivorship cohortScreening guidelinesAssociated with shorter timeIndex cancer
Academic Achievements & Community Involvement
Copy Link
Honors
honor The Population Science Research Prize
01/31/2017Other AwardYale Cancer CenterDetailsUnited Stateshonor The Distinguished Student Mentor Award
06/30/2016Other AwardYale School of Public HealthDetailsUnited States
News
Copy Link
News
- May 06, 2025
Genetic Test Underused in Cancer Care
- August 07, 2023
Screening Mammograms Carry Risks for Older Women, Study Finds
- March 05, 2023
Improving Care of Patients Receiving Advanced Cancer Treatment
- June 25, 2020Source: American Heart Association News
COVID-19 highlights long-term inequities in some communities
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
60 College Street
Academic Office
Ste 432
New Haven, CT 06510